Regenerative medicine is a broad field that aims to repair, replace, or restore cells, tissues, or function using approaches such as approved cell and gene therapies, tissue-engineered products, blood-derived preparations, biomaterials, and investigational biologics. A clinic label does not identify one treatment or level of evidence.
Established medicine and cash-pay marketing are not the same
FDA has approved specific cellular and gene therapy products for defined indications. In contrast, many products marketed by wellness or orthopedic clinics—umbilical cord, Wharton’s jelly, amniotic products, stromal vascular fraction, adipose-derived cells, exosomes, and “stem-cell” injections for pain or anti-aging—are not FDA-approved for those uses.
Common clinic categories
- PRP/PRF: autologous platelet-containing preparations with indication- and protocol-specific evidence.
- Bone marrow aspirate concentrate (BMAC): a heterogeneous autologous cell concentrate, not a purified stem-cell product.
- Cell and tissue products: regulatory status depends on source, processing, intended use, and other factors; “minimally manipulated” is not a universal exemption.
- Exosome or extracellular-vesicle products: no FDA-approved exosome products currently exist.
- Shockwave and acoustic treatments: physical-energy modalities rather than cell products, grouped here mainly by repair-oriented marketing.
- Peptides: a chemical class containing approved drugs and unapproved wellness compounds; not inherently regenerative.
Evidence must match product, route, and indication
A laboratory mechanism, animal study, or trial of one preparation cannot establish benefit for another. Cell source, donor, manufacturing, sterility, viability, dose, additives, route, target tissue, imaging guidance, rehabilitation, comparator, and outcome all matter.
Autologous does not mean approved or risk-free
Using a patient’s own blood, marrow, or fat may reduce some immune concerns but does not eliminate infection, contamination, bleeding, anesthesia, nerve or vessel injury, wrong-site administration, clotting, or inappropriate processing. Donor-derived products add communicable-disease, immune, manufacturing, and traceability concerns.
Clinic quality
A responsible clinic identifies the exact product and manufacturer, FDA status or IND, source and processing, lot and chain of custody, sterility testing, dose, route, imaging guidance, evidence for the exact indication, alternatives, rehabilitation plan, adverse-event reporting, total cost, and stopping rules.